Wechselwirkung zwischen Doravirin und Rifabutin
Doravirin und Rifabutin: Beide FDA-Fachinformationen versehen diese Kombination mit den stärksten Formulierungen, etwa einer Gegenanzeige, einem umrahmten Warnhinweis (Boxed Warning) oder der Anweisung, sie zu vermeiden.
Nicht ohne ärztliche Anleitung kombinieren. Die unten zitierten Formulierungen der Fachinformation sind die stärksten, die die FDA verwendet.
Was die FDA-Fachinformationen sagen
Aus der FDA-Fachinformation zu Rifabutin · Stand 2026-09-01
Therefore, co-administration with antiretroviral and anti-HCV drugs metabolized by CYP3A is not recommended or there may be a need to increase the dose of antiretroviral or anti-HCV drugs (see PRECAUTIONS-Drug Interactions ).
ND ↓ 50% in AUC, ↓ 68% in C 24 ↔ in C max If concomitant use is necessary, increase the doravirine dosage as instructed in doravirine-containing product prescribing information.
The concomitant use of protease inhibitors may require at least a 50% reduction in rifabutin dose, and depending on the protease inhibitor, an adjustment of the antiretroviral drug dose.
Co-administration with antiretroviral drugs metabolized by CYP3A, including but not limited to products containing bictegravir, elvitegravir, oral rilpivirine, or doravirine and anti-HCV drugs including but not limited to sofosbuvir (alone or in combination) may decrease plasma concentrations of those drugs, which may lead to loss of virologic response and possible…
Antiretroviral and Anti-HCV Drug Interactions Protease inhibitors act as substrates or inhibitors of CYP3A4 mediated metabolism.
Aus der FDA-Fachinformation zu Doravirin (PIFELTRO) · Stand 2026-07-08
PIFELTRO is contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of PIFELTRO [see Warnings and Precautions (5.2) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ] .
John's wort ( Hypericum perforatum) PIFELTRO is contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of PIFELTRO.
At least a 4-week cessation period is recommended prior to initiation of PIFELTRO. rifabutin ↓ doravirine Increase PIFELTRO dosage to one tablet twice daily when co-administered with rifabutin [see Dosage and Administration (2.2) ] .
Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy [see Contraindications (4) , Warnings and Precautions (5.2) , and Clinical Pharmacology (12.3) ] .
Sie nehmen mehr als diese beiden ein? Wechselwirkungen summieren sich. Prüfen Sie Ihre gesamte Liste auf einmal; sie bleibt in Ihrem Browser.
Im Wechselwirkungscheck öffnenKeine medizinische Beratung. Interaction Checker zitiert Texte aus FDA-Fachinformationen und NIH-Faktenblättern. Ob eine Wechselwirkung für Sie von Bedeutung ist, hängt von Dosierung, Einnahmezeitpunkt, Nieren- und Leberfunktion und weiteren Erkrankungen ab. Lassen Sie das in der Apotheke oder von Ihrer Ärztin bzw. Ihrem Arzt bestätigen.